Clinical Trial Update: Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating sorafenib for patients at risk of relapse after nephrectomy for renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Medical Research Council | Conditions: Kidney Cancer | Phase 3 | Status: COMPLETED